Morgan Stanley notes that Hims & Hers (HIMS) posted a “substantial beat” in Q1 and guided Q2 revenue below the Street and EBITDA essentially in line. After a 50% gain since the Novo Nordisk (NVO) partnership was announced, Hims & Hers “could see profit taking on a mixed earnings report,” according to the analyst, who keeps an Equal Weight rating and $40 price target on the shares following earnings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers Health: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Hims & Hers Health: Hold Rating Amid Market Challenges and Competitive Pressures
- Hims & Hers price target raised to $39 from $35 at Piper Sandler
- Buy Rating on Hims & Hers Health: Growth Potential in Weight Loss Segment and Future Revenue Targets
- Hims & Hers Health: Balancing Impressive Growth with Emerging Challenges – A Hold Recommendation